{reportSlug=global-chemotherapy-induced-acral-erythema-market, reportId=179723, mktKeyword=Chemotherapy-Induced Acral Erythema, cagr=2.90, publishDate=May 2023, priceOption2=6800, reportTitle=Chemotherapy-Induced Acral Erythema Comprehensive Study by Type (Analgesics, Anti-Inflammatory and Anti-Edematous Agents, Antihistaminic, NSAIDs, Oral/Topical Glucocorticoids, Pyridoxine (Vitamin B6), Others), Application (Pharmacy and Drugstores, Hospital Pharmacy, Online Drug Stores), Diagnosis Type (Graft versus host disease (GVHD), Steven Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN), Fixed drug eruption) Players and Region - Global Market Outlook to 2028, baseYr=2022, totalTableFig=217, priceOption1=3750, forecastYr=2028, noOfPages=178, reportKey=179232, breadcrum=Global Chemotherapy-Induced Acral Erythema Market}
We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Select User Access Type

Key Highlights of Report


May 2023 178 Pages 61 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Connect with Us
AMA Research Sales Support

Praveen Kumar

Head - Sales
AMA Research - Asia Pacific Client Engagement Partner

Filza Sayed

APAC Client Engagement Partner